Morris Elevado, MD
Gastroenterology · Cranston, RINPI 1417941105
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $179,811 of the $233,345 with a category attached, or 77.1%. AbbVie accounts for 62.6% of it on its own, with 39 other manufacturers making up the rest. Reporting peaked in 2019 at $68,250 and has fallen 76.0% since, to $16,394 in 2025. Among gastroenterology clinicians in RI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,676 payments — averaging $139.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$146K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$45K
- Takeda Pharmaceuticals U.S.A., Inc.$13K
- UCB, Inc.$10K
- Pfizer$4K
- Ironwood Pharmaceuticals, Inc$3K
- plus $12K from 34 others
Across 9 payments — averaging $3488.89 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$31K
What the payments were for
- Consulting fees$2,4301%
- Speaking & faculty fees$179,81177%
- Travel & lodging$22,1219%
- Food & beverage$28,78512%
- Education$1880%
- Gifts$100%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$233,345 in reported general payments places this provider in the 95th percentile of 85 gastroenterology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CreonLipase/Protease/Amylase | 107 | $316,409 |
| SucraidSacrosidase | 16 | $222,063 |
| RinvoqUpadacitinib | 20 | $169,605 |
| XifaxanRifaximin | 40 | $115,469 |
| LinzessLinaclotide | 116 | $106,927 |
| Humira(Cf) PenAdalimumab | 13 | $88,550 |
| RelistorMethylnaltrexone Bromide | 14 | $55,387 |
| Mesalamine | 73 | $34,055 |
| MotegrityPrucalopride Succinate | 54 | $30,283 |
| VoqueznaVonoprazan Fumarate | 21 | $16,843 |
| TrulancePlecanatide | 17 | $12,372 |
| Lubiprostone | 48 | $11,633 |
| Dexlansoprazole DrDexlansoprazole | 20 | $10,842 |
| Omeprazole | 696 | $10,500 |
| Pantoprazole Sodium | 889 | $9,500 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCreon, Rinvoq, Linzess | $146,139 | $592,941243 claims |
| QOL Medical, LLCSucraid | $838 | $222,06316 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan, Relistor, Trulance, Plenvu | $45,218 | $187,513102 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity, Dexilant | $13,008 | $34,61268 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $1,413 | $16,84321 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 85 gastroenterology providers in Rhode Island.
Other gastroenterology in Cranston
- Robert BierwirthCranston$603K
- Colin WoodardCranston$10K
- Thomas McGreenCranston$7K
- Robert WolfgangCranston$7K
- Paul RoderickCranston$5K
- Thomas SepeProvidence$307K
- Joseph LowneyWarwick$127K
- Paul AkermanProvidence$123K
- Sean FineProvidence$55K
- Breton RousselProvidence$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.